COMPASS Pathways plc (CMPS)
NASDAQ: CMPS · Real-Time Price · USD
3.760
+0.020 (0.53%)
At close: May 8, 2025, 4:00 PM
3.740
-0.020 (-0.53%)
Pre-market: May 9, 2025, 8:43 AM EDT
Company Description
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States.
It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa.
The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020.
The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
COMPASS Pathways plc
| Country | United Kingdom |
| Founded | 2020 |
| IPO Date | Sep 18, 2020 |
| Industry | Medical Care Facilities |
| Sector | Healthcare |
| Employees | 166 |
| CEO | Kabir Nath |
Contact Details
Address: 33 Broadwick Street London, W1F 0DQ United Kingdom | |
| Website | compasspathways.com |
Stock Details
| Ticker Symbol | CMPS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001816590 |
| CUSIP Number | 20451W101 |
| ISIN Number | US20451W1018 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Kabir Kumar Nath M.A., M.B.A. | Chief Executive Officer and Director |
| Teri Loxam M.B.A. | Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer |
| Dr. Guy Goodwin | Chief Medical Officer |
| Dr. Greg Ryslik Ph.D. | Chief Technology Officer |
| Stephen D. Schultz | Senior Vice President of Investor Relations |
| Anne Benedict | Chief People Officer |
| Lars Christian Wilde | Senior Advisor |
| Dr. Susan C. Stansfield Ph.D. | Advisor |
| Dr. Michael Gold M.D., M.Sc. | Chief Research and Development Officer |
| Lori Englebert M.B.A. | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 8, 2025 | 8-K | Current Report |
| May 8, 2025 | 10-Q | Quarterly Report |
| May 8, 2025 | 424B5 | Filing |
| May 7, 2025 | EFFECT | Notice of Effectiveness |
| May 7, 2025 | SCHEDULE 13G/A | Filing |
| Apr 28, 2025 | ARS | Filing |
| Apr 28, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 16, 2025 | PRE 14A | Other preliminary proxy statements |
| Apr 16, 2025 | 8-K | Current Report |
| Apr 15, 2025 | SCHEDULE 13G/A | Filing |